Table 1. Clinical, anthropometric, comorbidity characteristics, medications, and blood analysis in patients with T2DM.
| General and clinical data | N=51 |
|---|---|
| Age, years | 53.57 (9.35) |
| Male, n (%) | 28 (55) |
| Weight, kg | 86.11 (16.91) |
| Height, m | 1.69 (0.11) |
| Diagnostic time, months | 87.4 (69.8) |
| BMI, kg/m2 | 30.46 (5.29) |
| BSP, mmHg | 138.65 (19.43) |
| BDP, mmHg | 82.49 (10.50) |
| PP, mmHg | 41.69 (10.75) |
| MAP, mmHg | 100.43 (13.29) |
| HR, bpm | 70.43 (9.13) |
| cfPWV, m/s | 9.17 (1.72) |
| Risk factors | |
|---|---|
| Obesity, n (%) | 26 (50) |
| Obese class I, n (%) | 16 (61) |
| Obese class II, n (%) | 8 (31) |
| Obese class III, n (%) | 2 (8) |
| Smoker, n (%) | 5 (10) |
| Sedentary, n (%) | 18 (35) |
| Hypertension, n (%) | 26 (50) |
| Dyslipidemia, n (%) | 47 (92) |
| Menopause, n (%) | 14 (61) |
| Medications | |
|---|---|
| SGLT-2 inhibitors, n (%) | 10 (20) |
| Sulfonylurea, n (%) | 13 (25) |
| Biguanide, n (%) | 15 (29) |
| Glyptin, n (%) | 7 (14) |
| Insulin, n (%) | 17 (33) |
| Diuretic, n (%) | 8 (16) |
| Angiotensin-converting enzyme inhibitors, n (%) | 2 (4) |
| Angiotensin II receptor blockers, n (%) | 18 (35) |
| Beta-blockers, n (%) | 7 (14) |
| Lipid reducer, n (%) | 11 (20) |
| Blood analysis | |
|---|---|
| Insulin, mg/dL | 14.18 (8.85) |
| Glucose, mg/dL | 147.79 (51.60) |
| Hb1Ac, % [mmol/mol] | 8.22 [66] (1.80) |
| HDL-c, mg/dL | 45.92 (15.31) |
| LDL-c, mg/dL | 103.09 (42.49) |
| Triglycerides, mg/dL | 183.62 (128.20) |
| Total cholesterol, mg/dL | 179.16 (45.99) |
The data presented are described as mean (standard deviation) and in percentage of patients in the sample. BMI: body mass index; BSP: brachial systolic pressure; BDP: brachial diastolic pressure; PP: aortic pulse pressure; MAP: medium arterial pressure; HR: heart rate; cfPWV: carotid-femoral pulse wave velocity; SGLT-2: sodium/glucose cotransporter 2; Hb1Ac: glycated hemoglobin; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; T2DM: type 2 diabetes mellitus.